Protein matrix vaccines and related methods of making and administering such vaccines

Patent metadata

Field	Value
Publication number	US-9533032-B2
Application number	US-201514950113-A
Country	US
Kind code	B2
Filing date	Nov 24, 2015
Priority date	Aug 7, 2006
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

The invention relates to vaccine compositions having a carrier protein and an antigen of interest entrapped in a complex, methods of making such vaccines, and methods of vaccine administration.

First claim

What is claimed is:

1. A method of eliciting an immune response in a subject against an infectious agent, said method comprising administering to a subject in an amount sufficient to induce the production of antibodies in said subject a vaccine composition comprising an antigen of interest and a carrier protein matrix, wherein (i) said carrier protein matrix comprises covalently cross-linked carrier protein molecules, (ii) no more than 50% of said antigen of interest is covalently cross-linked to said carrier protein molecules, and (iii) said antigen is entrapped with said carrier protein matrix to form a complex.

2. The method of claim 1 , wherein said method comprises a second administering step wherein said vaccine composition is administered to said subject in an amount sufficient to boost the production of antibodies in said subject.

3. The method of claim 2 , wherein said production of antibodies is T-cell dependent.

4. The method of claim 1 , wherein said production of antibodies is sufficient to prevent or reduce infection of said subject by an infectious agent.

5. The method of claim 1 , wherein said infectious agent is pneumococcus, meningococcus, Haemophilus influenzae type B, Pseudomonas aeruginosa, Francisella tularensis, Shigella species, Salmonella species, Acinetobacter species, Burkholderia species, and Escherichia coli.

6. The method of claim 1 , wherein said method comprises a second administering step wherein a second vaccine composition comprising an antigen of interest is provided to said subject in an amount sufficient to boost the production of antibodies in said subject.

7. The method of claim 6 , wherein said production of antibodies is sufficient to prevent or reduce infection of said subject by a second infectious agent.

8. The method of claim 1 , wherein said antibodies are IgG antibodies.

9. The method of claim 6 , wherein said antibodies are IgG antibodies.

10. The method of claim 1 , wherein said subject is a human.

11. The method of claim 1 , wherein said antigen of interest is a polysaccharide, a polyalcohol, or a poly amino acid.

12. The method of claim 1 , wherein said antigen of interest comprises two or more antigens of interest.

13. The method of claim 11 , wherein said polysaccharide comprises at least 18 residues.

14. The method of claim 13 , wherein said polysaccharide is a Streptococcus pneumoniae polysaccharide, Francisella tularensis polysaccharide, Bacillus anthracis polysaccharide, Haemophilus influenzae polysaccharide, Salmonella typhi polysaccharide, Salmonella species polysaccharide, Shigella polysaccharide, or Neisseria meningitidis polysaccharide.

15. The method of claim 14 , wherein said Streptococcus pneumoniae polysaccharide is capsular type 1, 2, 3, 4, 5, 6A, 6B, 7A, 7B, 7C, 7F, 8, 9A, 9L, 9N, 9V, 10A, 10B, 10F, 11A, 11B, 11C, 11D, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16A, 16F, 17A, 17F, 18A, 18B, 18C, 18F, 19A, 19B, 19C, 19F, 20, 21, 22F, 23B, 23F, 24A, 24B, 24F, 25A, 25F, 27, 28A, 28F, 29, 31, 32A, 32F, 33A, 33B, 33D, 33F, 34, 35A, 35B, 35F, 36, 37, 38, 39, 40, 41A, 41F, 42, 43, 44, 45, 46, 47A, 47F, or 48.

Assignees

• Harvard College

Inventors

• Mekalanos John J

Classifications

• A61K39/092

  Streptococcus · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• A61K47/42

  Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34) · CPC title

• A61K39/0283

  Shigella · CPC title

• A61K39/02

  Bacterial antigens · CPC title